ABUS - Arbutus Biopharma GAAP EPS of -$0.10 beats by $0.01 revenue of $4.65M misses by $1.55M

2023-08-03 07:41:06 ET

• Arbutus Biopharma press release ( NASDAQ: ABUS ): Q2 GAAP EPS of -$0.10 beats by $0.01 .
• Revenue of $4.65M (-67.3% Y/Y) misses by $1.55M .
• The decrease of $9.5 million for the 2023 period was due primarily to lower revenue recognition from our license agreement with Qilu compared to the 2022 period based on lower employee labor hours expended by us in the 2023 period compared to the 2022 period to perform our manufacturing obligations under the license agreement.

For further details see: